Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Aug 22:16:100433.
doi: 10.1016/j.conctc.2019.100433. eCollection 2019 Dec.

Study protocol: Randomized controlled trial of web-based decision support tools for high-risk women and healthcare providers to increase breast cancer chemoprevention

Katherine D Crew  1   2   3 , Thomas B Silverman  4 , Alejandro Vanegas  4 , Meghna S Trivedi  1   3 , Jill Dimond  5 , Jennie Mata  1   3 , Margaret Sin  4 , Tarsha Jones  6 , Mary Beth Terry  2 , Wei-Yann Tsai  7 , Rita Kukafka  3   4   8
Affiliations

Study protocol: Randomized controlled trial of web-based decision support tools for high-risk women and healthcare providers to increase breast cancer chemoprevention

Katherine D Crew et al. Contemp Clin Trials Commun. .

Erratum in

Abstract

Background: Chemoprevention using selective estrogen receptor modulators and aromatase inhibitors has been shown to reduce invasive breast cancer incidence in high-risk women. Despite this evidence, few high-risk women who are eligible for chemoprevention utilize it as a risk-reducing strategy. Reasons for low uptake include inadequate knowledge about chemoprevention among patients and healthcare providers, concerns about side effects, time constraints during the clinical encounter, and competing comorbidities.

Methods/design: We describe the study design of a randomized controlled trial examining the effect of two web-based decision support tools on chemoprevention decision antecedents and quality, referral for specialized counseling, and chemoprevention uptake among women at an increased risk for breast cancer. The trial is being conducted at a large, urban medical center. A total of 300 patients and 50 healthcare providers will be recruited and randomized to standard educational materials alone or in combination with the decision support tools. Patient reported outcomes will be assessed at baseline, one and six months after randomization, and after their clinic visit with their healthcare provider.

Discussion: We are conducting this trial to provide evidence on how best to support personalized breast cancer risk assessment and informed and shared decision-making for chemoprevention. We propose to integrate the decision support tools into clinical workflow, which can potentially expand quality decision-making and chemoprevention uptake.

Trial registration: NCT03069742.

Keywords: Breast cancer risk; Chemoprevention; Decision support.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Study schema.
Fig. 2
Fig. 2
Multidisciplinary framework based on Shared Decision-Making (SDM) and Self-Determination Theory (SDT).
Fig. 3
Fig. 3
Sections of the RealRisks decision aid: A) Light narrative in graphic novel style, which include audio and Spanish translations; B) Dense narrative with key information about breast cancer risk and chemoprevention, including roll-overs with definitions of terms.
Fig. 4
Fig. 4
The BNAV toolbox.
See this image and copyright information in PMC

References

    1. Fisher B., Costantino J.P., Wickerham D.L. Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. J. Natl. Cancer Inst. 1998;90(18):1371–1388. - PubMed
    1. Vogel V.G., Costantino J.P., Wickerham D.L. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. J. Am. Med. Assoc. 2006;295(23):2727–2741. - PubMed
    1. Goss P.E., Ingle J.N., Ales-Martinez J.E. Exemestane for breast-cancer prevention in postmenopausal women. N. Engl. J. Med. 2011;364(25):2381–2391. - PubMed
    1. Nelson H.D., Smith M.E., Griffin J.C., Fu R. Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. Preventive Services Task Force. Ann. Intern. Med. 2013;158(8):604–614. - PubMed
    1. Visvanathan K., Chlebowski R.T., Hurley P. American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J. Clin. Oncol. 2009;27(19):3235–3258. - PMC - PubMed

Associated data